GB2610069B - HLA class II-restricted T cell receptors against RAS with G12V mutation - Google Patents

HLA class II-restricted T cell receptors against RAS with G12V mutation Download PDF

Info

Publication number
GB2610069B
GB2610069B GB2212195.8A GB202212195A GB2610069B GB 2610069 B GB2610069 B GB 2610069B GB 202212195 A GB202212195 A GB 202212195A GB 2610069 B GB2610069 B GB 2610069B
Authority
GB
United Kingdom
Prior art keywords
mutation
restricted
hla class
cell receptors
receptors against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2212195.8A
Other languages
English (en)
Other versions
GB2610069A (en
GB202212195D0 (en
Inventor
Levin Noam
Yoseph Rami
C Paria Biman
A Rosenberg Steven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of GB202212195D0 publication Critical patent/GB202212195D0/en
Publication of GB2610069A publication Critical patent/GB2610069A/en
Application granted granted Critical
Publication of GB2610069B publication Critical patent/GB2610069B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
GB2212195.8A 2020-02-26 2021-02-26 HLA class II-restricted T cell receptors against RAS with G12V mutation Active GB2610069B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062981856P 2020-02-26 2020-02-26
PCT/US2021/019775 WO2021173902A1 (en) 2020-02-26 2021-02-26 Hla class ii-restricted t cell receptors against ras with g12v mutation

Publications (3)

Publication Number Publication Date
GB202212195D0 GB202212195D0 (en) 2022-10-05
GB2610069A GB2610069A (en) 2023-02-22
GB2610069B true GB2610069B (en) 2025-04-16

Family

ID=74885105

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2212195.8A Active GB2610069B (en) 2020-02-26 2021-02-26 HLA class II-restricted T cell receptors against RAS with G12V mutation

Country Status (12)

Country Link
US (1) US20230159614A1 (enExample)
EP (1) EP4110804A1 (enExample)
JP (1) JP7742354B2 (enExample)
KR (1) KR20220143939A (enExample)
CN (1) CN115244075A (enExample)
AU (1) AU2021225872A1 (enExample)
BR (1) BR112022016661A2 (enExample)
CA (1) CA3169086A1 (enExample)
GB (1) GB2610069B (enExample)
MX (1) MX2022010157A (enExample)
TW (1) TWI900533B (enExample)
WO (1) WO2021173902A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060349A1 (en) * 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
WO2019112941A1 (en) * 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
WO2019180271A1 (en) * 2018-03-23 2019-09-26 Oslo Universitetssykehus Hf Method of diagnosing celiac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2022183167A1 (en) * 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060349A1 (en) * 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
WO2019112941A1 (en) * 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
WO2019180271A1 (en) * 2018-03-23 2019-09-26 Oslo Universitetssykehus Hf Method of diagnosing celiac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NIKOLICH-ZUGICH J ET AL,"THE MANY IMPORTANT FACETS OF T-CELL REPERTOIRE DIVERSITY",NATURE REVIEWS IMMUNOLOGY, NATURE PUB. GROUP, GB, vol.4, no.2, (2004-02-01) pages 123-132, ISSN 1474-1733, doi:10.1038/NRI1292, the whole document *

Also Published As

Publication number Publication date
CN115244075A (zh) 2022-10-25
EP4110804A1 (en) 2023-01-04
KR20220143939A (ko) 2022-10-25
AU2021225872A1 (en) 2022-09-15
GB2610069A (en) 2023-02-22
BR112022016661A2 (pt) 2022-10-11
US20230159614A1 (en) 2023-05-25
TWI900533B (zh) 2025-10-11
JP7742354B2 (ja) 2025-09-19
WO2021173902A1 (en) 2021-09-02
GB202212195D0 (en) 2022-10-05
CA3169086A1 (en) 2021-09-02
MX2022010157A (es) 2022-10-18
TW202140537A (zh) 2021-11-01
JP2023527613A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
GB2610069B (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
GB2609760B (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
GB2610311B (en) HLA class I-restricted T cell receptors against RAS with G12V mutation
SG11202002425PA (en) Hla class ii-restricted t cell receptors against mutated ras
IL275031A (en) HLA type I antigenic T cell receptors against mutated RAS
IL276554A (en) Non-HLA-restricted T-cell receptors and their uses
DK4219542T3 (da) T-cellereceptorer
IL262128A (en) T cell receptors
IL262124A (en) T cell receptors
IL262146A (en) T cell receptors
GB202305617D0 (en) Hla class ii-restricted dq t cell receptors against ras with g13d mutation
PL3430037T3 (pl) Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
DK3448882T3 (da) Anti-kk-lc-1-t-cellereceptorer
EP3381047A4 (en) BURNED MULTILAYER STACKS IN INTEGRATED CIRCUITS AND SOLAR CELLS
IL253922A0 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
BR112016002070A2 (pt) estrutura de anteparo
EP3259066A4 (en) Device, platform, and assay for assessing cells
BR112015000651A2 (pt) dispositivos de armazenamento de energia com pelo menos um substrato policristalino poroso
HK40085989A (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
TWI923548B (zh) 針對含有g12r突變之ras之hla第ii類限制性t細胞受體
HK40092965A (en) Hla class ii-restricted drb t cell receptors against ras with g12v mutation
HK40060430A (en) Hla class ii-restricted t cell receptors against ras with g12r mutation
HK40092098A (en) Hla class ii-restricted drb t cell receptors against ras with g12d mutation
EP3518294A4 (en) WIRING LINE MATERIAL FOR SOLAR CELL AND SOLAR CELL MODULE